Harmony Biosciences : HRMY 2023 JP Morgan Conference Presentation FINAL 1.5.23

41st Annual J.P. Morgan Healthcare Conference

January 2023

Forward Looking Statements

This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking

statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 28, 2022 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

2

Who We Are

OUR MISSION

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases.

3

Our Journey

FOUNDATION

GROWTH & EXPANSION

2017

2018

2019

2020

2021

2022

Secured Exclusive U.S. License	Granted Fast Track Status &	FDA Approves WAKIX for EDS in	Completed Nasdaq IPO	Initiated DM Phase 2	Initiated IH Phase 3
for WAKIX® from Bioprojet	Breakthrough Therapy	Narcolepsy (Aug)	(HRMY)	POC Trial	INTUNE Study
	Designation for Pitolisant
		Launched WAKIX (Nov)	Achieved $160M WAKIX Net	IND for Idiopathic Hypersomnia
	Filed NDA for Pitolisant		Sales in First Year of Launch	(IH) Opened
			Cataplexy Indication Approved		Signed 2022 Agreement with
Founded					Bioprojet
Harmony Biosciences	Launched KnowNarcolepsy		Initiated PWS Phase 2 POC Trial	WAKIX Added to AASM
		IND for Prader-Willi Syndrome		Treatment Guidelines	Achieved Positive Signals in
		(PWS) Opened	IND for Myotonic Dystrophy		PWS Phase 2 POC Trial
			(DM) Opened
					WAKIX Net Revenue
				HRMY Added to	+45% YoY Through Sep 2022
				Nasdaq Biotech Index (NBI)
					4

Harmony Today

A Rapidly Growing, Emerging Leader in the Neurology Arena

Strong Launch Success With

WAKIX® in Narcolepsy

>$1B+ Net Revenue

Opportunity Via Narcolepsy

and Additional Indications

Multiple Phase 2/3

Programs Underway to

Expand Utility of Pitolisant

Beyond Narcolepsy

Established Infrastructure and

Proven Capabilities Including

Clinical Development, Regulatory

Affairs, and Commercial

Award Winning Team and Culture

With Deep Expertise in

Rare-Orphan Neurology

5